{"groups":[{"description":"Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or up to 5 years.","id":"FG000","title":"Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"28"}],"type":"Reason Not Specified"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Missing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"61"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"59"}],"comment":"Response-evaluable population was defined as participants who received at least 1 dose of ixazomib, had measurable disease either during screening or before the first dose of study drug, and had a baseline and at least 1 postbaseline disease assessment.","type":"Response-evaluable Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"61"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with a diagnosis of relapsed and/or refractory multiple myeloma (RRMM) took part in the study to receive ixazomib + daratumumab + dexamethasone.","recruitmentDetails":"Participants took part in the study at investigative sites in Greece, the Czech Republic, the United States, Poland, France and the Netherlands from 13 March 2018 to 26 June 2023."}